In the BC patients group, the association between the ALU 260/111 or LINE-1 266/97 copy number ratio and other established clinical parameters, including tumor size, lymph node involvement, grading, and the status of estrogen receptor (ER), progesterone receptor (PR), and Her2/neu, is shown in Table 2. This evidence concerns the gene ESR1 and neoplasm.